Industry experts ask for regulatory guidelines and assurance on the value of well-designed Phase IIb dose-finding studies to help overcome long-standing resistance to sophisticated dose-finding strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Regulators and industry tackle dose-finding issues. Nat Rev Drug Discov 14, 371–372 (2015). https://doi.org/10.1038/nrd4644
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4644